TG Therapeutics revenue surges 70% to $205M; refinances debt, triples buyback to $300M

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~2 min read

Key Changes

• high

  Q1 2026 product revenue reached $201M, up 68% YoY, while net income nearly quadrupled to $20M. Company refinanced debt with $500M net raise and expanded share repurchase authorization from $100M to $300M, completing $100M in Q1 buybacks at $29.28/share.

  MD&A: Financial Performance & Capital Allocation verify on EDGAR →
• high

  Subcutaneous BRIUMVI Phase 3 trial completed enrollment ahead of schedule; topline data expected by Q1 2027. Simplified IV dosing Phase 3 also completed enrollment. Both lifecycle extensions could strengthen competitive positioning.

  MD&A: Clinical Development verify on EDGAR →
• high

  New executive order imposes up to 100% tariffs on imported patented pharmaceuticals under Section 232, with exceptions for companies with Most Favored Nation pricing agreements or onshore manufacturing. Could materially impact supply chain costs if applicable.

  Risk Factors: Trade Policy verify on EDGAR →